Package Leaflet: Information for the Patient
GLUINTOL 50 g Oral Solution
Glucose Monohydrate
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
|
Contents of the Package Leaflet:
GLUINTOL 50 is a glucose solution that belongs to the group of tests for diabetes and is indicated for use before the O'Sullivan Test for screening or pre-diagnosis of gestational diabetes.
Do not take GLUINTOL 50:
Warnings and Precautions
Consult your doctor, pharmacist, or nurse before taking GLUINTOL 50.
In patients with sodium deficiency, the administration of sodium-free solutions may cause peripheral circulatory collapse and oliguria (decreased urine output).
Taking GLUINTOL 50 with other medications
Tell your doctor, pharmacist, or nurse if you are taking, have recently taken, or may need to take any other medication.
There are certain medications that alter glucose metabolism and can affect the test results. Therefore, it is essential to limit the use of certain medications with hyperglycemic or hypoglycemic action during the 3 days prior to the test.
Medications with hyperglycemic action: Acetazolamide, adrenaline, etacrynic acid, nalidixic acid, nicotinic acid, tricyclic antidepressants, lithium carbonate, diazoxide, diphenylhydantoin, thiazide diuretics, estrogens, phenothiazines, furosemide, glucagon, glucocorticoids, heparin, indomethacin, morphine, nitrofurantoin, reserpine, etc.
Medications with hypoglycemic action (apart from sulfonylureas): Acetylsalicylic acid, amphetamines, clofibrate, cyproheptadine, ethanol, fenfluramine, guanethidine, haloperidol, MAO inhibitors, marijuana, oxytetracycline, propranolol, etc.
Taking GLUINTOL 50 with food, drinks, and alcohol
Glucose, as a carbohydrate, is present in most foods and beverages, alcoholic and non-alcoholic. To avoid glucose in the diet distorting the test result, the test will be preceded by a 10-12 hour overnight fast, during which only water can be consumed.
For the test to be representative of the individual's real state, it should be performed with the glucose solution after at least 3 days of an unrestricted diet (more than 150g of carbohydrates per day) and normal physical activity.
Pregnancy, Breastfeeding, and Fertility
GLUINTOL 50 is used in pregnant women for the pre-diagnosis of gestational diabetes.
Glucose crosses the placenta, while insulin does not, so the fetus itself is responsible for insulin synthesis. For this reason, it should be administered with caution in pregnant and breastfeeding women.
Driving and Using Machines
There is no indication that the glucose solution GLUINTOL 50 may affect the ability to drive or use machines.
Follow the administration instructions of this medication exactly as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The recommended dose for pre-diagnosis or screening of gestational diabetes is 50g; therefore, the contents of the bottle should be consumed in its entirety in a single use.
Between 7 and 9 am and after 30 minutes of rest, a blood sample is taken to determine basal glucose levels, and the patient ingests the glucose load 5 minutes later, with the first blood sample taken at a specific time after the basal sample, depending on the criteria used for interpreting the results. Generally, blood will be drawn at the time of glucose administration.
Use in Children and Adolescents
There is no specific recommendation for the use of GLUINTOL 50 in pregnant women under 18 years of age.
If you take more GLUINTOL 50 than you should
If you have used more GLUINTOL 50 than you should, consult your doctor, pharmacist, or nurse immediately, or call the Toxicology Information Service, phone 91-562 04 20, indicating the medication and the amount used. It is recommended to bring the packaging and package leaflet to the healthcare professional.
The symptoms of excess glucose include:
Like all medications, this medication can cause side effects, although not everyone will experience them.
GLUINTOL 50 may cause nausea, sweating, dizziness, or fainting after ingesting the glucose solution. If nausea, dizziness, sweating, or any other manifestation of vegetative nervous system hyperactivity occurs, a blood sample should be taken immediately, and the test should be interrupted and repeated later if deemed necessary. Other side effects that may occur include headache, feeling of fatigue, abdominal discomfort, and feeling of bloating.
After taking the glucose oral solution, an increase in heart rate without an increase in blood pressure has been observed in some cases.
Taking the glucose solution GLUINTOL 50 may cause a significant delay in gastric emptying in normal subjects.
Reporting Side Effects
If you experience any side effects, consult your doctor, pharmacist, or nurse, even if they are possible side effects not listed in this package leaflet. You can also report them directly through the Spanish Medicines Monitoring System www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date stated on the packaging after CAD. The expiration date is the last day of the month indicated. No special storage conditions are required.
Do not use this medication if you notice that the packaging shows visible signs of deterioration or if the solution is cloudy.
Medications should not be disposed of through wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Composition of GLUINTOL 50 g Oral Solution
Appearance of the Product and Package Contents
The product GLUINTOL 50 g Oral Solution is presented as a clear, reddish or orange solution without particles in suspension.
Each bottle contains 200 ml of oral solution.
Marketing Authorization Holder
INDUSEN, S.A.
Polígono Industrial Monte de la Abadesa, Unidad de Ejecución 38-02, parcela 3
09001 Burgos.
SPAIN
Manufacturer
INDUSEN, S.A.
Polígono Industrial Monte de la Abadesa, Unidad de Ejecución 38-02, parcela 3
09001 Burgos. SPAIN
or
IDIFARMA DESARROLLO FARMACÉUTICO, S.L.
Polígono Mocholí, Calle Noáin Nº1
31110 Noáin
Navarra - SPAIN
Detailed information on this medication is available on the website of the Spanish Agency for Medicines.
Date of the Last Revision of this Package Leaflet: May 2015
--------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
Dosage
200 ml administered over a period of 5 minutes.
The contents of the bottle should be consumed in its entirety.
Method of Administration
The O'Sullivan test consists of administering 278 mmol (50g) of glucose orally within the period between the 24th and 28th weeks of gestation, which is the period of maximum glucose intolerance.
The contents of the bottle should be consumed in its entirety in a single use.
Patient Preparation
To obtain reliable data, several rules must be strictly observed. During the 3 days preceding the test, a diet containing at least 150g of carbohydrates per day must be followed. If the patient has not previously followed a sufficiently carbohydrate-rich diet, the aforementioned regimen must be maintained for two more days. The presence of anorexia or any other circumstance that prevents adequate intake invalidates the test. It has been found that inactivity, such as bed rest, reduces glucose tolerance; therefore, glucose tolerance tests should not be performed in hospitalized patients. During the 10-12 hours preceding the test, the patient must fast strictly, even avoiding coffee. Smoking and exercise, even light, are also prohibited. The test should not be applied to patients who have been ill in the two weeks prior. Certain endocrine disorders, such as acromegaly, hyperthyroidism, or Cushing's syndrome, are often associated with abnormal glucose tolerance; therefore, before performing the test, the corresponding endocrine dysfunction must be corrected. Many medications, such as salicylates, diuretics, and anticonvulsants, decrease insulin secretion; they should be avoided for at least 3 days before the test, as well as all non-essential medications.
Performance and Interpretation of the Test
Between 7 and 9 am and after 30 minutes of rest, a blood sample is taken to determine basal glucose levels, and the patient ingests the glucose load 5 minutes later, with the first blood sample taken at a specific time after the basal sample, depending on the criteria used for interpreting the results. Generally, for the O'Sullivan test, blood will be drawn at the time of glucose administration.
After one hour, a venous blood sample is taken, and the glucose concentration is measured. If this concentration is greater than or equal to 7.8 mmol/L (140mg/dl), the result is considered positive, and the diagnostic test with a 100g glucose load should be performed.